Question-and-Answer Session
Operator
Thank you. First to Sharon Seiler with Ladenburg Thalmann.
Sharon Seiler - Ladenburg Thalmann
Good morning. A couple of questions on your clinical programs. First of all, with the Alzheimer's program, I think you said that you expected to complete that trial by year-end. My question here is, will we have results by year-end by way of press release or wait till you release them in a consent.
The second question would be, can you give us some detail on the trials you plan in patients for LX1031 and LX1032, and can you maybe provide some color on which programs you are looking to for additional INDs, either this year or next, as you go through your 10 programs by 2010?
Dr. Arthur Sands
This is Arthur Sands. All right. Okay, let's turn that over to Phil.
Dr. Philip Brown
So, thanks for the question Sharon . I think with regards to our Phase 2a study with 6171 in age-associated memory impairment, we are anticipating results by the end of this year. I anticipate being able to update you, the public in general with the top-line results when they become available. We'd certainly like to position them in at a major medical meeting as well, and obviously we'll have to evaluate them as they become available.
With regard to how we're going to pursue our patient studies with the 103 compounds. So 1031, we've announced today that we will initiate a study in irritable bowel syndrome in patients for a proof of concept to probe the importance of this mechanism in the setting of these patients.
We're still refining the details associated with that study, but as we've done with 6171, I feel that it's going to be an adequately powered or structured study in order to assess for the activity of the compound. So we'll certainly update you as we refine the protocol for that particular proof of concept study.
1032 of course is going to be positioned in patients with carcinoid syndrome. We are moving the compound through this multiple dose study in normals in order to select more rational dosing for use in patients. In other words, we believe that higher doses of the compound will be required in patients. So we want to make sure we understand that pharmacokinetic safety profile before we initiate that proof-of-concept study.
Lastly, the additional INDs anticipated for this year as Arthur mentioned are 4211, we are on track, we believe at present to support a filing in that, with that compound, which will be targeted for diabetes.
- To read the full transcript on Seeking Alpha, click here »
